Relmada CFO buys 200,000 shares in market

Relmada Therapeutics’ CFO bought 200,000 RLMD shares in open market trades around $4.20–$4.25 over two days.

Rhea-AI Filing Summary

RELMADA THERAPEUTICS, INC. (RLMD) reported that its Chief Financial Officer, Maged Shenouda, purchased a total of 200,000 shares of common stock in open market transactions on September 9 and 10, 2026. Purchases were made around $4.20–$4.25 per share, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 200,000 shares

Net Buy 2 txns

Insider Shenouda Maged

Role Chief Financial Officer

Bought 200,000 shs ($844K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	79,800	$4.25	$339K
Purchase	Common Stock F1, F2	120,200	$4.20	$505K

Holdings After Transaction: Common Stock — 1,000,000 shares (Direct)

Footnotes (2)

1. F1. The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
2. F2. Purchase prices range from $4.16 to $4.20 per share, inclusive.

Key Figures

Shares purchased September 9, 2026: 120,200 shares Weighted average price September 9, 2026: $4.20 per share Purchase price range September 9, 2026: $4.16–$4.20 per share +3 more

6 metrics

Shares purchased September 9, 2026 120,200 shares Open market purchase of RLMD common stock by the CFO

Weighted average price September 9, 2026 $4.20 per share Weighted average purchase price; individual trades from $4.16 to $4.20

Purchase price range September 9, 2026 $4.16–$4.20 per share Price range for multiple open market transactions

Shares purchased September 10, 2026 79,800 shares Open market purchase of RLMD common stock by the CFO

Price September 10, 2026 $4.25 per share Reported per-share purchase price for 79,800 shares

Total shares purchased 200,000 shares Aggregate of the CFO’s September 9–10, 2026 open market purchases

Key Terms

open market transactions, weighted average price, Rule 10b5-1 plan

3 terms

open market transactions market

"shares purchased in multiple open market transactions over a range of purchase prices"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

weighted average price financial

"The price reported represents the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Rule 10b5-1 plan regulatory

"no Rule 10b5-1 plan is reported for these transactions"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did RLMD report for its CFO?

Relmada Therapeutics reported that its CFO, Maged Shenouda, purchased 200,000 shares of RLMD common stock in open market transactions on September 9 and 10, 2026 at prices around $4.20–$4.25 per share.

How many RLMD shares did the CFO buy on each transaction date?

On September 9, 2026, the CFO purchased 120,200 shares of RLMD common stock. On September 10, 2026, he purchased an additional 79,800 shares, for a combined total of 200,000 shares acquired.

At what prices did the RLMD CFO purchase shares?

On September 10, 2026, the CFO bought 79,800 shares at $4.25 per share. On September 9, 2026, he bought 120,200 shares at a weighted average price of $4.20, with individual trades ranging from $4.16 to $4.20 per share.

Were the RLMD CFO’s share purchases under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 plan is reported for these transactions, meaning the open market purchases on September 9 and 10, 2026 are not affirmed as being made under a pre-arranged trading plan.

Are the RLMD CFO’s holdings after these purchases disclosed?

No resulting holdings are listed in the transaction data. The Form 4 reports the 200,000 RLMD shares purchased and the associated prices and dates, but it does not state the CFO’s total shares owned after these transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 07:30 AM EDT Accepted by SEC EDGAR 09/11/2026 - 07:30 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shenouda Maged

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES FLORIDA 33134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2026		P		120,200(1)	A	$4.2(2)	920,200	D
Common Stock	09/10/2026		P		79,800	A	$4.25	1,000,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

2. Purchase prices range from $4.16 to $4.20 per share, inclusive.

	/s/ Maged Shenouda	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)